Leukotriene modifiers. Expanded role may be on horizon.
Hayden
M L
ML
University of Virginia, Charlottesville, USA.
D000085:Acetates / Q000494:pharmacology / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000523:psychology; D003521:Cyclopropanes; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D007211:Indoles; D020024:Leukotriene Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010349:Patient Compliance; D048448:Phenylcarbamates; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D012449:Safety; D013256:Steroids; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D000085:Acetates; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D003521:Cyclopropanes; D007211:Indoles; D020024:Leukotriene Antagonists; D016859:Lipoxygenase Inhibitors; D048448:Phenylcarbamates; D011804:Quinolines; D013256:Steroids; D013440:Sulfides; D013449:Sulfonamides; D014105:Tosyl Compounds; C093875:montelukast; C063449:zileuton; D006918:Hydroxyurea; C062735:zafirlukast